Adakveo (crizanlizumab) – Revocation of EU marketing authorisation
15/06/2023
Medicines for human use
Direct healthcare professional communication (DHPC)
Adakveo (crizanlizumab): revocation of EU marketing authorisation due to lack of therapeutic efficacy